Top 10 HIV Clinical Developments of 2008 - CD8 T cells - The Body
Top 10 HIV Clinical Developments of 2008 - CD8 T cells - The Body
Top 10 HIV Clinical Developments of 2008 - CD8 T cells - The Body
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
50 • <strong>HIV</strong> JournalView—<strong>Top</strong> <strong>10</strong> <strong>HIV</strong> <strong>Clinical</strong> <strong>Developments</strong> <strong>of</strong> <strong>2008</strong><br />
15. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990<br />
to 2006. Clin Infect Dis. November 15, 2007;45(<strong>10</strong>):1369-1374.<br />
16. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for <strong>HIV</strong> testing <strong>of</strong> adults, adolescents, and<br />
pregnant women in health-care settings. MMWR Recomm Rep. September 22, 2006;55(RR14):1-17.<br />
17.<br />
Kuller LH, Tracy R, Belloso W, et al, for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and<br />
mortality in patients with <strong>HIV</strong> infection. PLoS Med. October 21, <strong>2008</strong>;5(<strong>10</strong>):e203.<br />
18. D:A:D Study Group. Use <strong>of</strong> nucleoside reverse transcriptase inhibitors and risk <strong>of</strong> myocardial infarction in <strong>HIV</strong>-infected<br />
patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. April 26, <strong>2008</strong>;371(9622):1417-1426.<br />
19. Sax P, Tierney C, Collier A, et al. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC)<br />
than ten<strong>of</strong>ovir/emtricitabine (TDF/FTC) as part <strong>of</strong> combination therapy in treatment-naive subjects with screening <strong>HIV</strong> RNA<br />
≥ <strong>10</strong>0,000 c/mL. In: Program and abstracts <strong>of</strong> the XVII International AIDS Conference; August 3-8, <strong>2008</strong>; Mexico City,<br />
Mexico. Abstract THAB0303.<br />
20. Smith K, Fine D, Patel P, et al. Efficacy and safety <strong>of</strong> abacavir/lamivudine compared to ten<strong>of</strong>ovir/emtricitabine in<br />
combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT study. In: Program and abstracts <strong>of</strong> the 15th<br />
Conference on Retroviruses and Opportunistic Infections; February 3-6, <strong>2008</strong>; Boston, Mass. Abstract 774.<br />
21. <strong>The</strong> SMART/INSIGHT and the D:A:D Study Groups. Use <strong>of</strong> nucleoside reverse transcriptase inhibitors and risk <strong>of</strong><br />
myocardial infarction in <strong>HIV</strong>-infected patients. AIDS. September 12, <strong>2008</strong>;22(14):F17-F24.<br />
22. Cutrell A, Hernandez J, Yeo J, Brothers C, Burkle W, Spreen W. Is abacavir (ABC)-containing combination antiretroviral<br />
therapy (CART) associated with myocardial infarction (MI)? No association identified in pooled summary <strong>of</strong> 54 clinical<br />
trials. In: Program and abstracts <strong>of</strong> the XVII International AIDS Conference; August 3-8, <strong>2008</strong>; Mexico City, Mexico.<br />
Abstract WEAB0<strong>10</strong>6.<br />
23. Pappa K, Hernandez J, Ha B, Shaefer M, Brothers C, Liao Q. Abacavir/lamivudine (ABC/3TC) shows robust virologic<br />
responses in ART-naive patients for baseline (BL) viral loads (VL) <strong>of</strong> ≥ <strong>10</strong>0,000 c/mL and < <strong>10</strong>0,000 c/mL by endpoint<br />
used in ACTG5202. In: Program and abstracts <strong>of</strong> the XVII International AIDS Conference; August 3-8, <strong>2008</strong>; Mexico City,<br />
Mexico. Abstract THAB0304.<br />
24. Hutter G, Nowak D, Mossner M, et al. Treatment <strong>of</strong> <strong>HIV</strong>-1 infection by allogeneic CCR5-D32/D32 stem cell<br />
transplantation: a promising approach. In: Program and abstracts <strong>of</strong> the 15th Conference on Retroviruses and<br />
Opportunistic Infections; February 3-6, <strong>2008</strong>; Boston, Mass. Abstract 719.<br />
25. Hassett JM, Zaroulis CG, Greenberg ML, Siegal FP. Bone marrow transplantation in AIDS. N Engl J Med. September 15,<br />
1983;309(11):665.<br />
26. Lane HC, Masur H, Gelmann EP, Fauci AS. <strong>The</strong>rapeutic approaches to patients with AIDS (PDF). Cancer Res. September<br />
1, 1985;45(Suppl 9):4674s-4676s.<br />
27. Lennox J, DeJesus E, Lazzarin A, et al. STARTMRK, a phase III study <strong>of</strong> the safety & efficacy <strong>of</strong> raltegravir (RAL)-based vs<br />
efavirenz (EFV)-based combination therapy in treatment-naive <strong>HIV</strong>-infected patients. In: Program and abstracts <strong>of</strong> the 48th<br />
Annual ICAAC/IDSA 46th Annual Meeting; October 25-28, <strong>2008</strong>; Washington, D.C. Abstract H-896a.<br />
28. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial <strong>of</strong> a novel CCR5 antagonist,<br />
maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment <strong>of</strong><br />
antiretroviral naive subjects infected with R5 <strong>HIV</strong>-1: week 48 results <strong>of</strong> the MERIT study. In: Program and abstracts <strong>of</strong> the<br />
4th International AIDS Society Conference on <strong>HIV</strong> Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney,<br />
Australia. Abstract WESS<strong>10</strong>4.
Change language